ThreeWire


WCG is a global leader in accelerating clinical research, providing solutions that improve the quality, efficiency, and safety of clinical trials. With over 55 years of experience, WCG connects sponsors, CROs, sites, and participants to deliver impactful therapies faster, maintaining high standards of human subject protection. WCG Biosafety Services, part of the WIRB-Copernicus IRB Group, specializes in biosafety and human gene transfer oversight, including the WCG Gene Therapy Advisory Board, which provides expert guidance in gene therapy research.

Industries

biotechnology
health-care
medical-device
pharmaceutical

Nr. of Employees

small (1-50)

ThreeWire

Eden Prairie, Minnesota, United States, North America


Products

Institutional CTMS platform

An institutional clinical trial management platform that centralizes study status, enrollment, calendars, budgets, billing and interfaces with electronic data capture and other systems.

Study acceleration solution (timeline reduction program)

A combined suite of feasibility, site-matching, IRB coordination and recruitment capabilities designed to shorten study timelines and improve enrollment predictability.

Trial feasibility and site-matching platform

A technology-enabled feasibility assessment and historical performance database used to match studies with sites and investigators based on prior performance metrics.

eCOA/ePRO patient-reported outcome platform

Electronic clinical outcome assessment and patient-reported outcome capture platform for standardized collection of trial endpoints.


Services

Centralized independent IRB review and oversight for industry, academic and multi-site trials, including single‑IRB solutions for multi-site studies.

Management of institutional biosafety committee processes and biosafety review for gene-transfer trials, including coordination of biosafety oversight across multiple IRBs and access to external gene-therapy advisory expertise.

Provision and management of endpoint adjudication committees and data monitoring committees, including recruitment of clinical, statistical and safety experts.

End-to-end drug safety operations covering adverse event processing, case management, aggregate reporting, medical information and compliance support.

Custom recruitment strategies combining on-site enrollment assistance, community outreach and permission-based digital engagement to improve enrollment and retention.

Site identification, feasibility, activation support, CTMS study build, financial management and training to accelerate study start-up and optimize site performance.

View All Services

Expertise Areas

  • Independent ethical review and single‑IRB coordination
  • Institutional biosafety and gene-transfer oversight
  • Gene therapy advisory and expert consultation
  • Participant recruitment, enrollment and retention strategies
  • Show More (8)

Key Technologies

  • Clinical trial management systems (CTMS)
  • Electronic trial master file (eTMF) integration
  • Electronic clinical outcome assessment (eCOA/ePRO)
  • Cloud-based document portals and submission workflows
  • Show More (6)

News & Updates

A virtual conference scheduled for October 20-24, 2025, available on demand until October 2026.

WCG's strategic acquisitions and partnerships in clinical research

WCG has acquired multiple companies including ThreeWire, Velos, KMR Group, MCC, Vigilare, ACI Clinical, and First Clinical Research, expanding its portfolio of solutions for clinical trial management, patient recruitment, data analysis, and regulatory support.

WCG's role in supporting IRB and IBC services

WCG provides independent review boards, IBC services, and solutions for ethical review, safety monitoring, and regulatory compliance, supporting over 2,300 institutions worldwide.

WCG's innovations in clinical trial technology and patient engagement

WCG develops and integrates advanced platforms like ClinSphere™, Velos eResearch, and partnerships with social networks like Inspire to enhance trial efficiency and patient recruitment.

Milestone of 4,000 IBC meetings

WCG's IBC Services has administered over 4,000 convened IBC meetings globally since 2001, reviewing over 310 human gene transfer trials.

Trusted partner for 92% of FDA-approved agents in last five years

WCG has been a key partner in clinical research, supporting the majority of FDA-approved therapies.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.